Petitioners challenging patents in IPR procedures may use various strategies to improve the likelihood of avoiding discretionary denial. One ...

In earlier blogs, we discussed when to amend and when not to amend claims in an inter partes review (“IPR”) pursuant to 35 U.S.C. § 316(d)(1). Below are guidelines on the procedural aspects of filing ...

Last week, a federal appellate court upheld on constitutional grounds a controversial procedure that has in recent years rendered thousands of patent claims invalid. In MCM Porfolio v. Hewlett-Packard ...

Genetic testing company GeneDx has turned to the Patent Trial and Appeal Board to try and invalidate 11 of Myriad Genetics patents, in a move that underlines the increasing popularity of inter partes ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Policy makers in Washington are closer than ever to passing legislative reforms that have the potential to rein in the high cost of prescription drugs in the United States. Substantial obstacles ...

Most claims are being accepted for trial and Delaware seems reluctant to grant stays: Scott Alter, Walter Linder and Robert O’Loughlin explain these and other conclusions from the first year of inter ...

Kenyon & Kenyon's new managing partner, Edward Colbert, takes over at a time of partner exits and lower demand for litigation. Colbert acknowledges that changes in patent law have affected his firm's ...